KOMBIGLYZE XR-1 | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

KOMBIGLYZE XR-1
Health Canada Patents

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

Contact Supplier

Chirogate is a professional Prostaglandin manufacturer.

Contact Supplier

Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

Contact Supplier

Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

Contact Supplier

jdmfs-not-supported-m-2025-06-30

KOMBIGLYZE XR-1

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

18 API Suppliers, 12 USDMF, 5 EU WC, 6 NDC API, 5 Listed Suppliers, $ API Reference Price

18 API Suppliers
12 USDMF
5 EU WC
6 NDC API
5 Listed Suppliers
$ API Reference Price

INTERMEDIATES

2 Intermediate Suppliers

2 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

41 FDF Dossiers, 30 FDA Orange Book, 2 Europe, 9 Canada

41 FDF Dossiers
30 FDA Orange Book
2 Europe
9 Canada

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 1 SPI Pharma, 5 DKSH, 4 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Aeon Procare, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Ashland, 1 BASF, 1 Clariant, 5 Corel Pharma Chem, 6 DFE Pharma, 7 Gangwal Chemicals, 2 Ideal Cures, 1 Ingredion Pharma Solutions, 17 Kerry, 3 Keval Exports, 1 Kima Chemical, 13 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 1 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 10 Roquette, 3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Silverline Chemicals, 1 The Dow Chemical Company, 3 Vasa Pharmachem

1 Rochem International Inc
1 SPI Pharma
5 DKSH
4 Gangwal Healthcare
2 Nanjing Well Pharmaceutical
1 Aeon Procare
5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
1 Ashland
1 BASF
1 Clariant
5 Corel Pharma Chem
6 DFE Pharma
7 Gangwal Chemicals
2 Ideal Cures
1 Ingredion Pharma Solutions
17 Kerry
3 Keval Exports
1 Kima Chemical
13 Microlex e.U
2 Nitika Pharmaceutical Specialities
1 Novo Excipients
1 Pharmatrans-Sanaq
3 Pluviaendo
3 Prachin Chemical
10 Roquette
3 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
10 Sigachi Industries
3 Silverline Chemicals
1 The Dow Chemical Company
3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders, 22 Coating Systems & Additives, 19 Direct Compression, 18 Thickeners and Stabilizers, 16 Granulation, 15 Disintegrants & Superdisintegrants, 12 Lubricants & Glidants, 8 Controlled & Modified Release, 8 Co-Processed Excipients, 7 Rheology Modifiers, 6 Film Formers & Plasticizers, 3 Emulsifying Agents, 3 Chewable & Orodispersible Aids, 3 Parenteral, 3 Taste Masking, 3 Solubilizers, 3 Topical, 2 API Stability Enhancers, 2 Coloring Agents, 1 Surfactant & Foaming Agents

31 Fillers, Diluents & Binders
22 Coating Systems & Additives
19 Direct Compression
18 Thickeners and Stabilizers
16 Granulation
15 Disintegrants & Superdisintegrants
12 Lubricants & Glidants
8 Controlled & Modified Release
8 Co-Processed Excipients
7 Rheology Modifiers
6 Film Formers & Plasticizers
3 Emulsifying Agents
3 Chewable & Orodispersible Aids
3 Parenteral
3 Taste Masking
3 Solubilizers
3 Topical
2 API Stability Enhancers
2 Coloring Agents
1 Surfactant & Foaming Agents

DIGITAL CONTENT

11 News #PharmaBuzz

11 News #PharmaBuzz

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 1 Annual Reports

8 US Medicaid Prescriptions
1 Annual Reports

MARKET PLACE

1 APIs

1 APIs

PATENTS & EXCLUSIVITIES

82 US Patents, 4 Health Canada Patents

82 US Patents
4 Health Canada Patents

$ API Ref.Price (USD/KG) : 13,143 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

4 All

01 4AstraZeneca Canada Inc.

filter Patent Reset all filters

4 All

01 22402894

02 22568391

filter Product Reset all filters

4 All

01 4Saxagliptin Hydrochloride

filter Dosage Reset all filters

4 All

01 4Tablet

filter Exp Date Reset all filters

4 All

01 22021-03-05

02 22025-05-26

Product Main Page

01

AstraZeneca Canada Inc.

Saxagliptin Hydrochloride

AGGSpend

Not Confirmed

AstraZeneca Canada Inc.

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-05-26

Date Granted : 2013-05-14

Saxagliptin Hydrochloride

Brand Name : ONGLYZA

Patent Number : 2568391

Filing Date : 2005-05-26

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2025-05-26

Date Granted : 2013-05-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

AstraZeneca Canada Inc.

Saxagliptin Hydrochloride

AGGSpend

Not Confirmed

AstraZeneca Canada Inc.

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-03-05

Date Granted : 2012-04-17

Saxagliptin Hydrochloride

Brand Name : ONGLYZA

Patent Number : 2402894

Filing Date : 2001-03-05

Strength per Unit : 5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2021-03-05

Date Granted : 2012-04-17

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

AstraZeneca Canada Inc.

Saxagliptin Hydrochloride

AGGSpend

Not Confirmed

AstraZeneca Canada Inc.

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-05-26

Date Granted : 2013-05-14

Saxagliptin Hydrochloride

Brand Name : ONGLYZA

Patent Number : 2568391

Filing Date : 2005-05-26

Strength per Unit : 2.5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2025-05-26

Date Granted : 2013-05-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

AstraZeneca Canada Inc.

Saxagliptin Hydrochloride

AGGSpend

Not Confirmed

AstraZeneca Canada Inc.

AGGSpend

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2021-03-05

Date Granted : 2012-04-17

Saxagliptin Hydrochloride

Brand Name : ONGLYZA

Patent Number : 2402894

Filing Date : 2001-03-05

Strength per Unit : 2.5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2021-03-05

Date Granted : 2012-04-17

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!